#Switzerland #Geneva #Neurotherapeutics #MindMaze Therapeutics #John W. Krakauer

MindMaze Therapeutics Welcomes Dr. John W. Krakauer as Strategic Advisor

MindMaze Therapeutics Holding SA, listed on the SIX Swiss Exchange under the ticker MMTX, has recently announced the appointment of Dr. John W. Krakauer as a strategic advisor. This significant move is aimed at bolstering the company's expansion efforts in the United States. CEO Zach Henderson expressed excitement about Dr. Krakauer's involvement, recognizing his substantial contributions to the scientific foundations of MindMaze's platform for neurorehabilitation.

Dr. Krakauer is not only a pioneering figure in the field of motor neuroscience but also the original scientific creator of the MindPod®, an innovative system designed for upper-limb rehabilitation. His expertise in neurorehabilitation and stroke recovery positions him as a key asset for MindMaze as it seeks to deliver precision neurotherapeutics to a broader patient population.

Henderson emphasized that Dr. Krakauer's decades of experience and insight into recovery processes will be instrumental as the company embarks on its next growth phase in the U.S. healthcare landscape.

Background of Dr. John W. Krakauer

Dr. Krakauer currently holds the esteemed John C. Malone Professorship at The Johns Hopkins University School of Medicine. He directs the Brain, Learning, Animation, and Movement (BLAM) Lab, as well as the Centre for Restorative Neurotechnology (CRN) at the Champalimaud Foundation in Lisbon, Portugal. His groundbreaking research has shaped the understanding of neuroplasticity and recovery paradigms, particularly through his development of high-dose, high-intensity training models.

In a landscape where traditional health systems have struggled to implement neurorehabilitation effectively, Dr. Krakauer's insights validate MindMaze's mission. He argues that for recovery to be truly effective, therapies must provide the correct dosage and intensity – concepts that MindMaze is striving to operationalize across various care settings, including at-home therapies.

Recent Achievements of MindMaze Therapeutics

The appointment of Dr. Krakauer comes at a time when MindMaze has been gaining significant traction in the market:

• - The company recently concluded a two-year multi-site real-world evidence program, which showcased notable improvements in patient mobility and self-care.
• - It achieved a remarkable 60% increase in therapies delivered daily and reported 17% higher community discharge rates compared to standard care.
• - Furthermore, a survey indicated that an impressive 87% of patients found the neurotherapy enjoyable.

In addition to these advancements, MindMaze has established its U.S. headquarters and a Patient Experience Center in Charlotte's Innovation District, further indicating its commitment to expanding its reach in the U.S. healthcare sector. Earlier this year, MindMaze also announced a strategic partnership with Vibra Healthcare, aimed at enhancing the delivery of its innovative neurotherapeutics.

The Future of Neurotherapeutics

As MindMaze continues to revolutionize neurorehabilitation, the integration of advanced technologies—including proprietary software, sensors, and AI-driven analytics—is a testament to its forward-thinking approach. The company's products, which have received FDA listing and CE marking, are designed to tackle the challenges posed by the shortage of specialized clinicians, ensuring that patients suffering from strokes, Parkinson's disease, and other neurological disorders receive scalable and effective treatments.

Dr. Krakauer's advisory role not only reinforces MindMaze's leadership but also bridges the gap between cutting-edge research and practical applications in therapy. With his guidance, the company is poised to drive the future of neurorestorative medicine, ensuring that it meets the needs of patients worldwide.